Updated 2025-2026 formulations of mRNA-1283 and BNT162b2 protect older adults against severe COVID-19 outcomes and medically attended illness.

On May 20, 2025, the Food and Drug Administration announced a new stance on who should receive the COVID-19 vaccine. The agency said it would approve new versions of the vaccine only for adults 65 ...

COVID-19 vaccination is still recommended for most older adults, including two doses a year for everyone over age 65 and anyone with a compromised immune system, and one dose a year for those under 65 ...

As the nation gears up for the rollout of an updated COVID-19 vaccine, a new study shows the economic benefits of continued broad vaccination in adults. In fact, the country would ultimately save more ...

This post was written by Laura Shannonhouse, Mary Chase Mize, Matthew Fullen, Jamie Aten, and Michael Porter. Previously, we talked about the perils of social isolation and loneliness, and how a lack ...

There are significant economic benefits of COVID-19 vaccination, particularly for older adults, with a single dose being cost-effective across all age groups. A second dose is economically favorable ...

The first influenza vaccine built on messenger RNA technology heads to US shelves this fall.

Health officials under US Health and Human Services Secretary Robert F. Kennedy Jr. are preparing analyses that may tie safety risks in pregnant women and children to the Covid-19 vaccine, while ...

The COVID-19 pandemic has exerted profound and multifaceted effects on the mental health of older adults worldwide. Widespread lockdowns and social-distancing measures heightened social isolation, ...

Known as Xocova, this is a once-daily pill that helps prevent the virus after exposure. When taken as prescribed, Xocova can reduce the likelihood of developing Covid-19 symptoms by 67%, according to ...

Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced U.S. availability of ...